Kids Neuroscience Centre, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia.
Functional Neuromics, Children's Medical Research Institute, The University of Sydney, Westmead, NSW, Australia.
Hum Mol Genet. 2023 Jun 5;32(12):2084-2092. doi: 10.1093/hmg/ddad035.
Recessive variants in the oxidoreductase PYROXD1 are reported to cause a myopathy in 22 affected individuals from 15 families. Here, we describe two female probands from unrelated families presenting with features of a congenital connective tissue disorder including osteopenia, blue sclera, soft skin, joint hypermobility and neuromuscular junction dysfunction in addition to known features of PYROXD1 myopathy including respiratory difficulties, weakness, hypotonia and oromotor dysfunction. Proband AII:1 is compound heterozygous for the recurrent PYROXD1 variant Chr12(GRCh38):g.21452130A>G;NM_024854.5:c.464A>G;p.(N155S) and Chr12(GRCh38):g.21462019_21462022del;NM_024854.5:c.892_895del;p.(V298Mfs4) and proband BII:1 is compound heterozygous for Chr12(GRCh38):g.21468739-21468741del;NM_024854.5:c.1488_1490del;p.(E496del) and Chr12(GRCh38):g.21467619del;NM_024854.5:c.1254+1del. RNA studies demonstrate c.892_895del;p.(V298Mfs4) is targeted by nonsense mediated decay and c.1254+1delG elicits in-frame skipping of exon-11. Western blot from cultured fibroblasts shows reduced PYROXD1 protein levels in both probands. Testing urine from BII:1 and six individuals with PYROXD1 myopathy showed elevated levels of deoxypyridinoline, a mature collagen crosslink, correlating with PYROXD1-disorder severity. Urine and serum amino acid testing of the same individuals revealed no reportable changes. In contrast to PYROXD1 knock-out, we find no evidence for disrupted tRNA ligase activity, as measured via XBP1 splicing, in fibroblasts expressing PYROXD1 variants. In summary, we expand the clinical spectrum of PYROXD1-related disorders to include an overlapping connective tissue and myopathy presentation, identify three novel, pathogenic PYROXD1 variants, and provide preliminary evidence that elevated urine DPD crosslinks may provide a clinical biomarker for PYROXD1 disorders. Our results advocate consideration of PYROXD1 variants in the differential diagnosis for undiagnosed individuals presenting with a connective tissue disorder and myopathy.
据报道,PYROXD1 氧化还原酶中的隐性变异可导致 15 个家族的 22 名受影响个体发生肌病。在这里,我们描述了来自两个无关家族的两名女性先证者,她们具有先天性结缔组织疾病的特征,包括骨质疏松症、蓝色巩膜、皮肤柔软、关节过度活动以及神经肌肉接头功能障碍,此外还具有已知的 PYROXD1 肌病特征,包括呼吸困难、无力、低张力和口运动功能障碍。先证者 AII:1 为常染色体隐性遗传,携带 12 号染色体(GRCh38):g.21452130A>G;NM_024854.5:c.464A>G;p.(N155S)和 12 号染色体(GRCh38):g.21462019_21462022del;NM_024854.5:c.892_895del;p.(V298Mfs4),先证者 BII:1 为常染色体隐性遗传,携带 12 号染色体(GRCh38):g.21468739-21468741del;NM_024854.5:c.1488_1490del;p.(E496del)和 12 号染色体(GRCh38):g.21467619del;NM_024854.5:c.1254+1del。RNA 研究表明,c.892_895del;p.(V298Mfs4)被无义介导的衰变靶向,c.1254+1delG 导致外显子 11 的框内跳跃。来自培养成纤维细胞的 Western blot 显示,两名先证者的 PYROXD1 蛋白水平降低。对 BII:1 和 6 名 PYROXD1 肌病患者的尿液检测显示,脱氧吡啶啉(一种成熟的胶原交联物)水平升高,与 PYROXD1 疾病的严重程度相关。同一批个体的尿液和血清氨基酸检测没有发现可报告的变化。与 PYROXD1 敲除相反,我们发现,在用携带 PYROXD1 变异的成纤维细胞测量时,没有证据表明 tRNA 连接酶活性受到破坏,这可以通过 XBP1 剪接来衡量。总之,我们将 PYROXD1 相关疾病的临床谱扩展到包括重叠的结缔组织和肌病表现,确定了三个新的、致病性的 PYROXD1 变异,并提供了初步证据表明,尿液 DPD 交联物升高可能为 PYROXD1 疾病提供临床生物标志物。我们的研究结果主张在诊断为未确诊的结缔组织疾病和肌病患者时,考虑到 PYROXD1 变异。